Organon’s Q3 Results Meet Analyst Expectations
As FDA Accepts Filing For Denosumab Biosimilar
After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.
